Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site

 

 

 

Novartis Oncology Media

Cancer Research at Novartis Oncology

This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room

Research

Please visit the Novartis Oncology Pipeline, which includes compounds in all phases of development, starting with preclinical studies in tumor cell line and animal models through large Phase III randomized trails.

Everolimus Press Releases

EVEROLIMUS CONTACT

Denise Brashear
Novartis Oncology Global Public Relations
office +1 862-778-7336
 
Heather Bochner
Novartis Oncology Global Public Relations
office +1 862-778-5092

01-Jul-2010
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients

05-Jun-2010
Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis

03-Jun-2010
Pivotal Phase III trial of Novartis drug Afinitor® met primary endpoint in study of patients with
advanced pancreatic
neuroendocrine tumors

Everolimus Materials

 

SEARCH OUR WEBSITES

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.

 
 

Novartis Oncology

Oncology News is a current news service provided by Doctor's Guide®. Novartis accepts no responsibility for and makes no representations or warranties regarding the content of the information presented.

Ok